Firstly, the marked immunogenicity of PDGFRA mutant GIST as shown by Vitiello et al. (which by our findings may be only restricted to the D842V mutant), together with the lack of an oncogene-signature, could in part explain the known indolent course of this subset of GIST, irrespective to the recognized prognostic factors. The gene discussed is PDGFRA; the disease is gastrointestinal stromal tumor.